Skip to main content
    P

    PTC Therapeutics Inc (PTCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $63.49
    +0.13 (+0.21%)

    Market Cap: $5.30B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    PTC Therapeutics Inc (PTCT) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    PTC Therapeutics (PTCT) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, PTC Therapeutics reported EPS of $0.61, above the $0.17 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    36%(14/39)
    Avg Surprise
    +5.25%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.40
    Range$0.09 - $0.94
    17 analysts
    Revenue Consensus
    $336.93M
    Range$297.21M - $365.40M
    15 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.52
    Range-$0.01 - $1.38
    7 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.21+145.5%
    60d ago$0.19+169.0%
    30d ago$0.14+279.6%
    7d ago$0.37+40.9%
    Current$0.52
    Revenue Consensus
    $313.41M
    Range$291.64M - $341.40M
    5 analysts

    Next Report

    PTCT has an expected report date of Feb 17, 2027.

    PTCT Earnings Call

    The latest PTCT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, PTCT beat 14, missed 24 and matched 1. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 641.18% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.61$0.17N/A+258.82%Beat+221.1%31 up, 1 downOct 29, 2026N/A
    Jun 30, 2026$0.92-$0.17N/A+641.18%BeatN/A30 up, 0 downJul 30, 2026$360.52M
    Mar 31, 2026-$0.03-$0.44-$0.44 - -$0.44+93.18%Beat-100.3%10 up, 1 downMay 7, 2026$272.55M
    Dec 31, 2025-$1.80-$0.40-$1.17 - $1.23-350.00%MissN/A40 up, 1 downFeb 19, 2026$164.68M
    Sep 30, 2025$0.19-$1.11-$1.30 - -$0.87+117.12%BeatN/A72 up, 2 downNov 4, 2025$211.01M
    Jun 30, 2025-$0.83-$1.07-$1.27 - -$0.96+22.43%BeatN/A41 up, 0 downAug 7, 2025$178.88M
    Mar 31, 2025$10.04-$0.70-$1.15 - -$0.26N/AN/AN/A21 up, 0 downMay 6, 2025$1.18B
    Dec 31, 2024-$0.34-$0.65-$0.94 - -$0.16+47.45%BeatN/A32 up, 0 downFeb 27, 2025$213.17M
    Sep 30, 2024-$1.36-$1.66-$2.09 - -$0.91+18.07%BeatN/A131 up, 0 downNov 7, 2024$196.79M
    Jun 30, 2024-$1.27-$0.95-$1.65 - -$0.73-33.68%MissN/A122 up, 0 downAug 8, 2024$186.70M
    Mar 31, 2024-$1.20-$1.10-$1.93 - -$0.56-9.09%MissN/A132 up, 0 downApr 25, 2024$210.12M
    Dec 31, 2023-$0.24$0.50-$1.10 - $1.47-148.00%MissN/A132 up, 0 downFeb 29, 2024$307.06M
    Sep 30, 2023-$1.75-$1.55-$1.81 - -$0.70-12.90%MissN/A122 up, 0 downOct 26, 2023$196.58M
    Jun 30, 2023-$1.58-$1.71-$3.04 - -$0.58+7.60%BeatN/A132 up, 0 downAug 3, 2023$213.81M
    Mar 31, 2023-$1.88-$1.63-$1.96 - -$0.46-15.34%MissN/A162 up, 1 downApr 27, 2023$220.38M
    Dec 31, 2022-$1.89-$1.59-$2.32 - -$0.22-18.87%MissN/A150 up, 0 downFeb 21, 2023$167.41M
    Sep 30, 2022-$1.53-$1.26-$1.97 - -$0.71-21.43%MissN/A141 up, 1 downOct 27, 2022$217.13M
    Jun 30, 2022-$2.13-$1.48N/A-43.92%MissN/AN/A1 up, 0 downAug 4, 2022$165.53M
    Mar 31, 2022-$1.78-$1.66-$2.10 - -$1.06-7.23%MissN/A104 up, 0 downMay 3, 2022$148.74M
    Dec 31, 2021-$2.03-$1.65-$2.60 - -$1.04-23.03%MissN/A113 up, 0 downFeb 22, 2022$165.23M
    Sep 30, 2021-$1.89-$1.89-$2.14 - $0.050.00%In lineN/A102 up, 0 downOct 28, 2021$138.74M
    Jun 30, 2021-$1.68-$1.82-$2.11 - -$1.50+7.69%BeatN/A9N/AJul 29, 2021$116.68M
    Mar 31, 2021-$1.83-$1.62-$2.05 - -$1.13-12.96%MissN/A11N/AMay 4, 2021$117.94M
    Dec 31, 2020-$1.08-$0.94-$1.58 - -$0.23-14.89%MissN/A12N/AFeb 25, 2021$237.27M
    Sep 30, 2020-$1.03-$0.45-$2.12 - $9.14-128.89%MissN/A13N/AOct 29, 2020N/A
    Jun 30, 2020-$1.80-$1.56-$1.72 - -$0.93-15.38%MissN/A10N/AAug 5, 2020$75.24M
    Mar 31, 2020-$1.81-$1.33-$1.73 - -$0.92-36.09%MissN/A9N/AApr 30, 2020$68.26M
    Dec 31, 2019-$1.37-$0.71-$0.78 - -$0.16-92.96%MissN/A9N/AMar 2, 2020$96.46M
    Sep 30, 2019-$0.89-$0.88-$0.92 - -$0.45-1.14%MissN/A9N/AOct 29, 2019$71.42M
    Jun 30, 2019-$0.65-$0.61-$0.88 - -$0.35-6.56%MissN/A9N/AAug 6, 2019$85.52M
    Mar 31, 2019-$0.91-$0.68-$0.83 - -$0.60-33.82%MissN/A7N/AMay 2, 2019$53.58M
    Dec 31, 2018-$0.58-$0.32-$0.47 - -$0.11-81.25%Miss-2033.3%7N/AFeb 28, 2019$32.75M
    Sep 30, 2018-$1.06-$0.49-$0.68 - -$0.11-116.33%MissN/A8N/ANov 5, 2018$107.18M
    Jun 30, 2018-$0.21-$0.44-$0.45 - -$0.04+52.27%BeatN/A6N/AAug 7, 2018$68.74M
    Mar 31, 2018-$0.46-$0.38-$0.71 - -$0.19-21.05%MissN/A6N/AMay 9, 2018$56.06M
    Dec 31, 2017$0.03-$0.14-$0.69 - $0.10+121.43%BeatN/A7N/AMar 6, 2018$78.03M
    Sep 30, 2017-$0.82-$0.67-$0.94 - -$0.29-22.39%MissN/A7N/ANov 2, 2017$41.85M
    Jun 30, 2017-$0.44-$0.86-$2.82 - -$0.81+48.84%BeatN/A5N/AAug 8, 2017$47.96M
    Mar 31, 2017-$0.85-$0.93N/A+8.60%BeatN/AN/AN/AMay 8, 2017$26.55M
    Dec 31, 2016-$0.78-$1.07N/A+27.10%BeatN/AN/AN/AMar 16, 2017$25.19M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $7.60, a profit after a loss of $4.17 per share the year before. It was -$4.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$7.60N/A
    Dec 31, 2024-$4.17N/A
    Dec 31, 2023-$5.45N/A
    Dec 31, 2022-$7.33N/A
    Dec 31, 2021-$7.43N/A
    Dec 31, 2020-$5.72N/A
    Dec 31, 2019-$3.82N/A
    Dec 31, 2018-$2.31N/A
    Dec 31, 2017-$2.08N/A
    Dec 31, 2016-$4.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 19 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,21819
    2026Q2Jun 30, 20269,01418
    2026Q1Mar 31, 20266,72918
    2025Q4Dec 31, 20258,56817
    2025Q3Sep 30, 20256,99418
    2025Q2Jun 30, 20257,80521
    2025Q1Mar 31, 20257,87013
    2024Q4Dec 31, 20248,80119

    2026Q3 Earnings Call

    Opening remarks

    Ellen Cavaleri Head of Investor Relations Good afternoon, and thank you for joining us to discuss PTC Therapeutics' Third Quarter 2026 Corporate Update and Financial Results. I am joined today by our Chief Executive Officer, Dr. Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Pierre Gravier. Today's call will include forward-looking statements based on our current expectations. These statements are subject to certain risks and uncertainties, and actual results may differ materially. Please review the slide posted on our Investor Relations website in conjunction with the call, which contains information about our forward-looking statements and our most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the SEC, as well as our other SEC filings, for a detailed description of applicable risks and uncertainties that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. Additionally, we will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and reconciliation of GAAP to non-GAAP are available in today's earnings release. I will now pass the call over to our CEO, Dr. Matthew Klein.

    Matthew Klein CEO Thank you all for joining us today. I'm pleased to share the results of another quarter of record product revenue and solid execution across the company. In the third quarter, we achieved total revenue of $358 million, including $276 million of product revenue, led by continued quarter-over-quarter growth of Sephience sales in the U.S. and internationally. Based on this performance, we are raising our full-year 2026 product revenue guidance to $960 million to $990 million and now expect total revenue of $1.29 billion to $1.32 billion. This updated guidance represents 64% to 69% year-over-year product revenue growth. In addition, with our continued effective expense management, we expect to achieve our goal of reaching cash flow breakeven in 2026. Beginning with Sephience, we are now one year into the global launch, which by all measures has been a great success, and all signs point to Sephience being a blockbuster rare disease product. In the third quarter, worldwide Sephience revenue was $182 million, led by consistent growth in the U.S. and continued expansion internationally. As of September 30, we have over 2,000 active patients on Sephience worldwide. In the U.S., we continue to see strong underlying demand across all patient segments. Over the course of the third quarter, we saw an uptick in branded and generic Kuvan switches, with continued penetration into the therapy-naive and tried-and-failed patient segments. Adherence remains strong, reinforcing the meaningful benefits patients are experiencing on therapy, including diet liberalization, cognitive function, and mood improvements.

    Frequently Asked Questions About PTCT

    When is PTC Therapeutics's next earnings date?

    PTC Therapeutics's next earnings report is expected for Feb 17, 2027.

    Did PTCT beat earnings estimates last quarter?

    Yes. PTC Therapeutics reported EPS of $0.61 for the quarter ended Sep 30, 2026, above the $0.17 estimate, a 258.82% surprise.

    What EPS do analysts expect from PTCT next quarter?

    The consensus EPS estimate for PTC Therapeutics for the quarter ending Dec 31, 2026 is $0.40 from 17 analysts, with estimates from $0.09 to $0.94.

    How often does PTCT beat earnings estimates?

    PTC Therapeutics beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +106.03%.